Investors Home Financials SEC Filings
SEC Filings
NASDAQBLFS
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2011Calendar Year 2010Calendar Year 2009Calendar Year 2008Calendar Year 2007Calendar Year 2006Calendar Year 2005Calendar Year 2004Calendar Year 2003Calendar Year 2002Calendar Year 2001Calendar Year 2000Calendar Year 1999Calendar Year 1998Calendar Year 1997Calendar Year 1996Calendar Year 1995
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
CT ORDERConfidential treatment orderDec 17, 2014Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
SC 13D/AAmendment to a SC 13D filingNov 20, 2014Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Aug 18, 2014Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
SC 13D/AAmendment to a SC 13D filingJun 02, 2014Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
CT ORDERConfidential treatment orderMar 27, 2014Open Confidential treatment order in HTML.Open Confidential treatment order in DOC file.Open Confidential treatment order in PDF file.Open Confidential treatment order in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Mar 26, 2014Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
CERTNASWhen a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNASMar 26, 2014Open When a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNAS in HTML.Open When a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNAS in DOC file.Open When a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNAS in PDF file.Open When a company wishes to "uplist" from pinksheets to NASDAQ it must first file S-1 and S-1a until final approval. Once final approval is obtained the SEC files a CERTNAS in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Mar 26, 2014Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
EFFECTNotice from the SEC of registration effectivenessMar 20, 2014Open Notice from the SEC of registration effectiveness in HTML.Open Notice from the SEC of registration effectiveness in DOC file.Open Notice from the SEC of registration effectiveness in PDF file.Open Notice from the SEC of registration effectiveness in XLS file.
CORRESPCorrespondence from the Filer to the SECMar 19, 2014Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
CORRESPCorrespondence from the Filer to the SECMar 10, 2014Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerMar 06, 2014Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECMar 03, 2014Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerFeb 28, 2014Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECFeb 14, 2014Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerFeb 06, 2014Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECJan 22, 2014Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.
UPLOADCorrespondence from the SEC to the FilerJan 09, 2014Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.

We believe the promise of cell and gene therapies starts with the integrity of a single cell

Free
Sample
Request
Free
Sample
Request

Advancing the future of cell and gene therapy

The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.

We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.

Work with experts who understand your biopreservation challenges

Connect with
our experts

Ask the Scientists
Ask the Scientists
Notch-Bottom-25px

Explore our
solutions

General Inquiries
General Inquiries
Notch-Bottom-25px
Notch-Right-25px
Notch-Bottom-25px

Collaborative and comprehensive CDMO support

At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.

Learn more
Learn more

Regulatory
readiness

Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.

Learn more
Learn more
Notch-Left-25px
Notch-Bottom-25px

STORE

CellSeal®
CryoCase

Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates

Shop now
Shop now
Notch-Right-25px
Notch-Bottom-25px

Data-driven
decision making

Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.

Evidence Library
Evidence Library

Insights

News
APD_240715_BioLifeSolutions_Edit069-scaled
Insights-Notch
May 21, 2025

Designing the Ideal Cryostorage Container for CGT

Read more
News
Two female scientists in lab coats reviewing data on a tablet in a laboratory setting.
Insights-Notch
April 18, 2025

The Cell Summit ’25: A Must-Attend Event for Innovators in Cell & Gene Therapy

Read more
Cryopreservation
Patient undergoing apheresis procedure with blood drawn through tubing connected to a machine that separates blood components, while a healthcare worker in protective gear monitors the process.
Insights-Notch
March 27, 2025

Optimizing Biopreservation Strategies for Apheresis-Derived Cells in Immunotherapeutic Applications

Read more
News
Early Preparation for IND and BLA Submissions. Illustration of the phases of vaccine clinical trials, showing a progression from preclinical research to Phase 1, Phase 2, Phase 3, and regulatory approval, with icons representing laboratory testing, small and large groups of participants, and final distribution.
Insights-Notch
February 19, 2025

How to prepare early for regulatory submissions from IND to BLA

Read more
View more
View more

Preserve, protect and expand cell performance

Mastering
Biopreservation

Discover
Discover

Ensure Regulatory Submission Readiness

Discover
Discover

Automate & Close
CGT Processes

Discover
Discover

Protect & Expand
Cell Performance

Discover
Discover